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Abstract
ELISA and FTIR assay techniques were 
used to identify HER2 gene expression 
in the blood serum of female dogs and to 
characterise the biochemical composition. 
ELISA tests assess the stage of primary 
tumour development and evolution, while 
FTIR allows for a complete characterisation 
of biomolecules associated with the tumoral 
process. Blood serum samples from 30 
female dogs were analysed. Concentrations 
of the HER2/neu protein were detected 
using ELISA kits specific for canine and 
human detection. Infrared spectroscopy 
(IR) was conducted in absorbance mode at 
a frequency range of 400–4000 cm-1 and a 
resolution of 4 cm-1 over 50 scans. The ELISA 
cut-off for HER2 protein concentration in 
blood serum was determined using the 
receiver operating characteristic (ROC) 
curve and by estimating the area under the 
curve (AUC) at a 95% confidence interval 
(CI=95%). The ROC curves in the canine 
and human ELISA tests were 0.75 and 0.45, 
respectively. The representative IR spectra 
for HER2 gene expression corresponded to 
lipids (1161 cm-1, 1452 cm-1, 2851 cm-1). This 
study contributes to the knowledge of HER2 
through the identification of biochemical 
features associated with the changes in the 
HER2/neu+ and HER2/neu- states.
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Introduction
Canine mammary tumour (CMT) is a 
common pathology in female dogs (Moe, 
2001; Zatloukal et al., 2005; Vacellari et al., 
2009; Gal et al., 2016) and is characterized 
by high mortality levels (Silva et al., 
2014), where one of four dogs over the 
age of two years with this tumour may 
die (Hemanth et al., 2015). Growth factors 
(GFs) are polypeptides that stimulate 
cellular proliferation through high-
affinity binding to membrane receptors 
(Goustin et al., 1986). This signalling 
process leads to autocrine growth 
phenomena that are typical of neoplastic 
transformation (Surmacz, 2003; Witsch 
et al., 2010). Human epidermal growth 
factor receptors (EGFR/HER) are part of a 
family of receptor tyrosine kinases (RTK) 
(Biscardi et al., 2000). The EGFR group 
includes four members: HER1 (ErbB1), 
HER2/neu (ErbB2), HER3 (ErbB3), and 
HER4 (ErbB4) (Ceballos & Hernández, 
2008). The HER2 proto-oncogene is 
located on chromosome17q21 in humans 
(Fukushige et al., 1986) and 1q13.1 in 
canines (Murua-Escobar et al., 2001). This 
gene encodes the 185-kDa transmembrane 
protein HER2/neu (Akiyama et al., 1986) 
that contains an intracellular tyrosine 
kinase domain (ICD), a transmembrane 
domain, and an extracellular domain 
(ECD) with a mass of 105 kDa, which is 
measurable in blood serum (Ha et al., 
2014; Di Gioia et al., 2015). Active HER2 
receptors stimulate cellular proliferation 
and tumour progression (Gutiérrez 
and Shiff, 2011; Ressel et al., 2013), but 
not necessarily tumour malignisation 
(Rungsipipat et al., 1999; Martin de las 
Mulas et al., 2003; Carney et al., 2004; 
Ressel et al., 2013; Ferreira et al., 2014; 
Silva et al., 2014; Burrai et al., 2015; 
Campos et al., 2015). 
HER2 is highly important in the 
prognosis of human breast cancer 
(HBC) development (Savino et al., 2009) 
since it is associated with resistance 
to chemotherapy and hormonal 
treatments, leading to reduced survival 
of patients with overexpression of 
this gene (Surmacz, 2003; Ceballos & 
Hernández, 2008). In canines, SNP-based 
studies have shown that mutations in 
HER2 are silent and could represent a 
natural variation in this gene (Hsu et 
al., 2009). However, silent SNPs can 
affect the kinetics of protein synthesis 
and generate diverse configurations 
of the final proteins (Kimchi-Sarfaty 
et al., 2007; Komar, 2007), ultimately 
challenging diagnosis and follow-up. 
The use of serum and blood-based 
biomarkers in cancer studies allows 
achieving a broad perspective of 
the biochemical characteristics and 
dynamics of cancer; furthermore, 
these markers are especially relevant 
when biopsies are difficult to perform 
(Jesneck et al., 2009). The enzyme-linked 
immunosorbent assay (ELISA) is used 
to evaluate the stage of primary tumour 
development by enabling the monitoring 
of changes in HER2 during the evolution 
of the mammary tumour (Carney et 
al., 2004). In humans, a serum HER2 
(sHER2) concentration of 15 ng/mL is 
the most appropriate test cut-off value 
to measure the levels of this protein in 
blood (Tse et al., 2005; Fehm et al., 2007; 
Zhang et al., 2018), yet other authors 
have determined a cut-off of 22 ng/mL 
(Savino et al., 2009). Despite this, due to 
the wide variations in sHER2 levels, its 
clinical value is prognostic, particularly 
related to tumour progression and 
therapeutic response (Carney et al., 
2004, 2013). In canines, there is still no 
definitive diagnostic cut-off (Campos et 
al., 2015). 
Fourier-transformed infrared spec-
troscopy (FTIR) is a simple and rapid re-
agent-free method that is non-destructive 
and requires a small amount of sample 
(Zelig et al., 2015). Most cancer lesions are 
identified at the spectral region between 
800 and 1800 cm-1 (fingerprint); this range 
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comprises the majority of functional 
groups, such as carbonyl, carbon-nitro-
gen, amino, methyl, methylene, carboxy, 
among others (Lima et al., 2015; Ferreira 
et al., 2020). However, the spectral region 
from 2800 to 3000 cm-1, called the first 
lipid region (Gavgiotaki et al., 2016), is 
also of interest due to its relevance in the 
study of HER2.
The ELISA technique is capable of 
discriminating between specific proteins 
and can thus identify these molecules in 
blood serum. This study focused on the 
gene expression of HER2 in canine serum 
by using ELISA to identify the expression 
features of the protein, and to determine 
the biochemical characteristics based on 
functional groups analysis by using FTIR. 
Materials and methods
Sample collection and conservation
Samples from female dogs diagnosed 
with CMT (n=14) and healthy females 
(n=6) were examined between May 2018 
and March 2019. At the time of sample 
collection, not all patients had a definitive 
diagnosis of the tumour type. A total of 
4 mL blood was collected bv aseptic 
venipuncture using an evacuated tube 
without anticoagulant (BD Vacutainer, 
Becton Drive), with a clot retraction time 
of three hours at room temperature. 
Samples were centrifuged at 3000 rpm 
for 10 minutes (Tuck et al., 2009). The 
resulting serum was stored at -80°C and 
multiple cycles of freezing and thawing 
were avoided. Samples exhibiting any 
deterioration were discarded.
ELISA – measurement of HER2 protein 
levels in blood serum
The Canine Epidermal Growth Factor 
Receptor 2 (Her2Ab) ELISA kit ref. 
MBS2606515 (MyBioSource, San Diego, 
CA, USA) and the Human HER2 Platinum 
ELISA kit ref. BMS207-2 (eBioscience, 
Vienna, Austria) were used to detect and 
quantify HER2 protein levels in blood 
serum. Assays were performed according 
to manufacturer’s instructions. All assays 
were performed in duplicate, including 
the control with known concentrations 
(soluble fragment of the HER2 protein 
(p185HER2) and a canine standard (HER2)). 
Measurements were performed on a 
Rayto RT-2600c (Guangming, Shenzhen, 
China) microplate reader. 
The prognostic criteria for classifying 
patients with overexpression according 
to the cut-off values were: 1. Patients with 
CMT and measurement of sHER2 equal 
to or above the cut-off: true positive (TP 
= CMT - HER2/neu+); 2. Control patients 
with a measurement of sHER2 below 
the cut-off: true negative (TN = Healthy 
- HER2/neu-); 3. Patients with CMT and 
measurement of sHER2 below the cut-off: 
false negative (FN = CMT - HER2/neu); 4. 
Control patients with a measurement of 
sHER2 equal to or above the cut-off: false 
positive (FP = Healthy - HER2/neu+).
Acquisition of FTIR spectra
FTIR analysis was performed on 5 µL 
blood serum at room temperature. The 
IR spectra were acquired using an Alpha 
ATR Platinum spectrometer (Bruker 
Corporation, Germany). The optimal 
measurement conditions were at room 
temperature (20°C) and 40% relative 
humidity. For readings, each sample 
was placed on a diamond crystal tip. The 
reading parameters were absorbance 
mode, frequency range 400–4000 cm-1, 
and resolution of 4 cm-1 with 50 scans per 
sample. Readings from water were used 
as blank runs that were subsequently 
subtracted from the spectra of the 
samples (Elmi et al., 2017; Santos et al., 
2019; Macotpet et al., 2020). 
Spectral data processing
Processing and analysis of the 
original spectra were performed using 
OriginPro 9.0.0 (OriginLab Corporation, 
Northampton, MA 01060 USA). Each 
spectrum was normalized and baseline 
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correction performed according to the 
Savitzky–Golay method with a 2nd order 
polynomial and 20 data points (Lima et 
al., 2015; Zelig et al., 2015; Macotpet et al., 
2020). The prognostic criteria of cut-off 
values from the ELISA tests were used to 
identify the characteristics of the spectra 
for HER2/neu expression. The frequency 
ranges selected for this analysis included 
the fingerprint region, 800–1800 cm-1 
(Ghimire et al., 2020; Macotpet et al., 
2020), which was divided into four 
subregions (800–1100 cm-1, 1100–1380 cm-
1, 1380–1700 cm-1, 1700–1800 cm-1), and 
a spectral region from 2800 to 3000 cm-1 
since it is relevant for the study of HER2/
neu (Gavgiotaki et al., 2016; Ferreira et al., 
2020). 
The segments of the selected spectra 
were analysed based on second-order 
derivatives to allow the detection of 
minor peaks in bands from the main 
spectral regions and to differentiate 
between patterns from ill and healthy 
individuals (Zeling et al., 2015; Ghimire 
et al., 2020). For this, the spectra were 
softened using the Savitzky–Golay 
method with a 2nd order polynomial and 
20 data points. The area under the curve 
(AUC) for each spectrum (original and 
second-order derivative) was calculated 
mathematically into a polygon area with 
an absolute measurement type. The 
functional groups and vibrational modes 
were assigned according to previous 
findings by several authors. The AUC 
ratio was expressed as the relative area 
under the curve (RAUC).
Statistical analysis 
The following accuracy parameters 
were analysed from the ROC curve to 
determine the optimal ELISA cut-off: 
Youden’s index (J) as the maximum 
vertical distance between the ROC curve 
and the diagonal (Schisterman et al., 
2005), sensitivity (Sn) and specificity (Sp), 
minimum distance to the top-left corner as 
the minimum distance between the ROC 
curve and the left upper corner) (Hajian-
Tilaki, 2013). The area under the curve 
(AUC) was determined to estimate the 
discriminant capacity of each assay. The 
prognostic criteria for the classification 
of patients according to TP, TN, FP, and 
FN allowed for the establishment of 
the predictive positive value (PPV) and 
predictive negative value (PNV). 
The absorbance values obtained 
from the canine and human ELISA tests 
and the IR spectra (original and second 
derivative) were checked for normality 
using the Shapiro-Wilks test. Based 
on the results from the normality test, 
parametric tests were used for normal 
distributions and non-parametric 
tests for non-normal distributions. A 
confidence interval of 0.95 was set and a 
P-value <0.05 was considered statistically 
significant. All statistical analyses were 
performed using R v.3.2.2, NCSS 11 
(NCSS, LLC. Kaysville, Utah, USA), and 
OriginPro 9.0.0. 
Ethical aspects
This study was conducted with the 
approval of the Ethics Committee on 
Animal Experimentation, Faculty of 
Agropecuary Sciences, Universidad 
de Caldas (CEEA Code-15061601). All 
dog owners authorised the collection of 




The samples analysed corresponded 
to seven breeds: Maltese, Miniature 
Schnauzer, Cocker Spaniel, French 
Poodle, English Bulldog, Pitbull, 
Samoyed, and mixed-breed. The average 
age was 9.3 years old. 
ELISA
Based on the ROC curves, the optimal 
cut-off and AUC for the canine and 
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human ELISA tests were ≥0.31 ng/mL and 
0.75, ≥9.26 ng/mL and 0.45, respectively 
(Table 1). The PPV and PNV of canine 
and human ELISA test was 83% and 50% 
and 78% and 36%, and the accuracies for 
each test were 70% and 55%, respectively. 
Of the 20 female dog samples, the canine 
ELISA tests discriminated that 14 were 
HER2/neu+ (TP=71%, FP=29%) and six 
were HER2/neu- (TN=67%, FN=33%). 
Moreover, the human ELISA tests 
yielded TP=50%, FP=50%, TN=67%, and 
FN=33%. The Shapiro-Wilks normality 
test showed statistically significant 
differences (P<0.05), except for ELISA 
HER2-negative patients (P=0.13).
FTIR spectra in blood serum in HER2/
neu positive-negative female dogs
The study of HER2-positive and 
negative states was based mainly on the 
similar results between the canine and 
human ELISA tests, which showed that 
TP and FN individuals display malignant 
and benign lesions, such as mammary 
carcinoma and benign adenoepithelioma, 
whereas TN and FP females are clinically 
healthy. The original infrared spectra from 
blood serum (Figure 1) showed six main 
spectral peaks in the ranges 800 to 1800 
and 2800 cm-1, corresponding to proteins, 
esters, nucleic acids, phospholipids, and 
lipids. 
The peaks with the highest 
absorbance are associated with clinically 
healthy HER2/neu-positive females. Table 
2 summarizes the vibrational modes 
assigned and the corresponding blood 
serum composition according to the 
literature.
The second-order derivatives of the 
infrared spectra identified 13 additional 
representative peaks that were assigned to 
four subregions. Specifically, subregion 1 
(800–1100 cm-1) included phospholipids, 
Table 1. Accuracy parameters and optimal cut-








Cut-off Value ≥ 0.31 ng/mL
≥ 9.26 
ng/mL
Sensibility (%) 71 50
Specificity (%) 67 67
PPV (%) 83 78
PNV (%) 50 36







J (95% CI) b 0.381 0.1667
Sensibility + 
Specificity 1.381 1.166
Distance to Corner 0.439 0.6009
aAccuracy = Proportion of correctly classified patients
bJ = Youden Index. Sensibility + Specificity-1.
Figure 1. FTIR original spectra for females with 
CMT and healthy female dogs. Absorbance bands 
of the main functional groups at frequency ranges 
from 800 to 1800 cm-1 for HER2/neu positive 
females (red lines) and HER2/neu negative 
females (blue lines)
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Table 2. Main vibrational modes assigned to the original FTIR spectra in canine blood serum (described 
in Figure 2) according to various references.
Spectra (cm-1) Organic compound/Vibrational mode assignment References
1073 Phospholipids: vs(PO2) Oleszko et al., 2015
1238 Protein: Amide III Ferreira et al., 2020
1304 Lipids Bi et al., 2014; Depciuch et al., 2016
1398 Phospholipids/fatty acids, amino acids: vs(COO-) Kar et al., 2019
1447 Protein (methyl groups), lipids: CH3 asymmetric bending [δas (CH3)]
Kar et al., 2019; 
Ferreira et al., 2020
1546 Protein: Amide II [v (N–H) v (C–N)] Ferreira et al. 2020
1636 Protein: Amide I [v (C=O), v(C–N), δ (N–H)] Ferreira et al., 2020
v = stretching vibrations, δ = bending vibrations, s = symmetric vibrations, as = asymmetric vibrations




Organic compound/Vibrational mode 
assignment References
848 Tyrosine proteins
Bi et al., 2014; Zelig et 
al., 2015; Depciuch et 
al., 2016
995 Ester bands: vs(C-O) Elmi et al., 2017; Ferreira et al., 2020
1161 Protein/Carbohydrate/lipid ester bonds: CO–O–C asymmetric stretching (vas (CO-O-C))
Ferreira et al., 2020; 
Oleszko et al., 2015
1314 Protein: Amide III Ferreira et al., 2020
1352 Protein: Amide III Elmi et al., 2017
1452 Lipid and protein: Methylene bending Bi et al., 2014; Ferreira et al., 2020
1510 Tyrosine proteins: v(C-C) Kar et al., 2019
1727 Lipids/ester bands: Gavgiotaki et al., 2016
1768 Ester Elmi et al., 2017
2851 Lipids, long-chain fatty acids: vs(CH2) Oleszko et al., 2015
2884 Lipid: CH3 asymmetric stretching (vas (CH3)) Elmi et al., 2017; Ferreira et al., 2020
2920 Nucleic acid/Lipids, long-chain fatty acids: CH2 asymmetric stretching (vas (CH2))
Kar et al., 2019; 
Ferreira et al., 2020
2989 Phospholipids/cholesterol: Gavgiotaki et al., 2016
v = stretching vibrations, δ = bending vibrations, s = symmetric vibrations, as = asymmetric vibrations.
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tyrosine-protein, esters; subregion 2 
(1100–1380 cm-1) included amide III, 
carbohydrates, lipids; subregion 3 (1380–
1700cm-1) corresponded to phospholipids, 
fatty acids, lipids, amide I, amide II, 
and tyrosine protein; and subregion 
4 (1700–1800 cm-1) showed lipids and 
esters. Additionally, the region 2800 to 
Figure 2. Detail of the second-derivative spectra and most representative frequencies. Spectra (a) 
800–1100 cm-1, (b) 1100–1380 cm-1, (c) 1380–1700 cm-1, (d) 1700–1800 cm-1, (e) 2800–3000 cm-1 for 
HER2/neu positive females (red lines) and HER2/neu negative females (blue lines)
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3000 cm-1 was characterized by lipids, 
phospholipids, and cholesterol (Figure 
2). The description of the vibrational 
modes and the corresponding functional 
groups is shown in Table 3.
Four groups were established 
according to the type of spectra from 20 
peaks (original and second derivatives): 
group 1, proteins; group 2, lipids; 
group 3, esters; and group 4, mixed. 
No statistically significant differences 
were found within each group and the 
diagnostic categories (Table 4). 
The RAUC showed differences 
between states, indicated by a higher 
abundance of peaks corresponding to 
lipids for HER2/neu+ (1161 cm-1, 1398 cm-
1, 1452 cm-1, 2851 cm-1, 2920 cm-1), except 
at 1447 cm-1 and 2884 cm-1 and 1304 cm-1 
peak and amide I (1636 cm-1). The RAUC 
for tyrosin-type proteins (848 cm-1, 1510 
cm-1), amide III (1314 cm-1, 1352 cm-1), 
and amide II (1546 cm-1) were greater 
for HER2/neu-, as were esters (995 cm-
1, 1768 cm-1) and phospholipids at 2989 
cm-1. These findings indicate that amide 
I and lipid-related functional groups are 
a product of HER2 gene overexpression. 
Discussion
This study contributes to the 
knowledge of HER2 regarding gene 
expression and detection in blood serum, 
its clinical relevance in CMT research, 
and its application as a model for human 
breast cancer (HBC). We demonstrated 
the likelihood of using canine and human 
antigens to determine and compare 
sHER2 concentrations. The canine ELISA 
tests yielded TP = 71%, TN = 67%, FP = 
33%, and FN = 29%, whereas the human 
ELISA test showed 50%, 67%, 33%, and 
50%, respectively. Although there is high 
homology between the human and canine 
HER2 antigens (Singer et al., 2012), our 
findings demonstrate that the use of the 
human HER2 protein is not adequate to 
evaluate the concentration of this protein 
in canine serum, in agreement with 
Campos et al. (2015). This is likely due to 
the low capacity of canine antibodies to 
recognize human HER2. These findings 
indicate that the antigenic determinants 
from the two molecules are not the same, 
perhaps due to differences in the tertiary 
structure of the proteins (Kimchi-Sarfaty 
et al., 2007; Komar, 2007; Hsu et al., 2009) 
or cross-reaction with other members of 
the HER family (Burrai et al., 2015). Both 
tests coincided in 29% (4/14) of TP females, 
TN 33% (2/6), FN 50% (3/6), FP 7% (1/14). 
Our results on the overexpression of the 
HER2/neu protein are similar to previous 
reports (Dutra et al., 2004; Ressel et al., 
2013; Shinoda et al., 2014; Campos et al., 
2015). 
A positive correlation has been 
determined between the presence of 
HER2 in blood serum and tumour 
tissue (Campos et al., 2015), tumour 
mitotic index, high histological grade 
and size (Muhammadnejad et al., 
2012; Silva et al., 2014), although no 
significant differences have been found 
between HER2 expression in benign and 
malignant tumours (Kim et al., 2011; 
Ressel et al., 2013), indicating that HER2 
may participate in tumour formation and 
rapid progression of CMT (Dutra et al., 
2004; Ferreira et al., 2009; Bertagnolli et 
al., 2011), but not necessarily in malignant 
transformation, or at least, it is not a good 
marker of malignancy (Kaszak et al., 
2018). The clinical association of HER2 is 
controversial (Hsu et al., 2009; Ressel et 
al., 2013; Burrai et al., 2015; Campos et 
al., 2015). Unfortunately, in this study it 
was not possible to compare the ELISA 
and FTIR findings with histological 
parameters due to limited availability of 
biopsies.
Based on infrared spectroscopy, we 
analysed diverse biochemical patterns, 
such as proteins, lipids, esters, nucleic 
acids, and carbohydrates. Although we 
did not obtain significant differences, 
distinct features between HER2/neu-
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positive and negative states were observed 
for certain functional groups, such as 
the relative intensity at the peak at 1636 
cm-1. Furthermore, this study analysed 
an additional region between 2800 and 
3000 cm-1 that had not been studied in 
CMT. Previous research on HER2 using 
infrared spectroscopy, among other 
biochemical analysis techniques in cells, 
tissues, and fluids, reported changes 
in the compositional profile, especially 
regarding lipids (CH2, CH3), which were 
found to be higher in the HER2/neu-
positive state (Hartsuiker et al., 2010; Bi 
et al., 2014; Gavgiotaki et al., 2016). These 
reports agree with the findings reported 
here, except for the peaks at 1304, 1447 
and 2884 cm-1. Moreover, high contents 
of lipids in cytoplasmic organelles are 
reported in HER2+ HBC cell cultures 
(Hartsuiker et al., 2010; Gavgiotaki et al., 
2016), which are involved in the adhesion 
and migration of epithelial tumour 
cells (Murai, 2012). Similarly, several 
studies have detected an increase in 
phospholipids, associated with fatty acids 
and cholesterol synthesis (Menendez 
and Lupu, 2007; Bi et al., 2014; Elmi et 
al., 2017; Kar et al., 2019). This pattern 
was only observed at the peak 1398 cm-1 
(phospholipid, fatty acid, and amino acid 
complex). This phenomenon is caused by 
the regulation of the fatty acid synthase 
associated with a low regulation of 
tyrosine kinase receptors (Jin et al., 2010).
On the other hand, we report an 
increase in amide I, especially in HER2/
neu+. However, amide I not necessarily 
is associated with HER2 overexpression. 
Several authors report an increase in 
this protein in HBC (Elmi et al., 2017; 
Chrabaszcz et al., 2018), but a consistent 
variation is not observed in HER2+ cell 
cultures (Bi et al., 2014). Amide I and 
amide II are reported in greater amounts 
in hyperplastic tissues (Tian et al., 2015); 
however, a reduction of amide II and an 
increase of amide I suggest a possible 
malignisation process (Simonova & 
Karamancheva 2014). A reduction of 
amide III has been observed in HER2+ 
cell cultures (Bi et al., 2014), which is 
consistent with our findings. 
FTIR enables the non-invasive 
recognition of tissue alterations through 
markers of cellular activity. In this study, 
we detected Sn 93% and Sp 100%. This 
agrees with recent studies in dogs that 
identified the most important spectra in 
cancer using blood serum and reported Sn 
and Sp of 76.7% and 87.5%, respectively 
(Macotpet et al., 2020) and Sn 100% and 
Sp 100% in conformational proteins in 
HBC (Ghimire et al., 2020).
Given the analogies between both 
species (Rowell et al., 2011; Pinho et 
al., 2012), and the homology between 
human and canine HER2 antigens, 
immunotherapy seems to be promising 
in canine patients with HER-2 expression 
(Singer et al., 2012; Kaszak et al., 2018). 
However, additional markers associated 
with the expression of this gene must 
be considered in order to elucidate the 
prognostic value of HER2 overexpression 
in female dogs.
This study has enabled the recognition 
of important features of HER2 through 
discriminant ELISA tests and several 
biochemical characteristics based on 
spectral patterns in a biological fluid, 
such as blood serum. Future studies 
should address the amplification of 
the IR spectra described here using 
nanoparticles in blood serum from 
ELISA HER2/neu-positive or negative 
patients. Finally, the results of the FTIR 
identified two possible control peaks of 
HER2 overexpression, corresponding to 
the regions surrounding the peak 1636 
cm-1 and a band between 2800–3000 cm-1, 
which were associated with amide I and 
the corresponding lipids (CH2, CH3), 
respectively.
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Ova studija primijenila je ELISA i 
FTIR tehnike za identifikaciju ekspresije 
HER2 gena u krvnom serumu kujica i za 
karakterizaciju biokemijskog sastava. ELISA 
testovi procjenjuju fazu razvoja i evolucije 
primarnog tumora, a FTIR omogućuje 
potpunu karakterizaciju biomolekula 
povezanih s tumorskim procesom. 
Analizirali smo uzorak krvnog seruma 
30 kujica. Detektirali smo koncentracije 
HER2/neu proteina uporabom dva ELISA 
kompleta za detekciju u pasa, odnosno 
ljudi. Infracrvena spektroskopija (IR) je 
provedena u apsorpcijskom načinu pri 
frekvencijskom rasponu od 400-4000 cm-1 
i rezoluciji od 4 cm-1, 50 skenova. Odredili 
smo ELISA graničnu vrijednost (cut-off) za 
koncentraciju HER2 proteina u krvnom 
serumu uporabom krivulje karakteristika 
primatelja-operatora (ROC) i procjenom 
površine ispod krivulje (AUC) uz interval 
pouzdanosti od 95 % (CI=95 %). ROC 
krivulje u ELISA testovima za pse i ljude bile 
su 0,75, odnosno 0,45. Reprezentativni IR 
spektri za ekspresiju HER2 gena odgovarali 
su lipidima (1161 cm-1, 1452 cm-1, 2851 cm-
1). Ova studija doprinosi poznavanju HER2, 
putem identifikacije biokemijskih svojstava 
povezanih s promjenama u HER2/neu+ i 
HER2/neu- stanjima.
Ključne riječi: ErbB2, infracrvena 
spektroskopija, imunoanaliza, onkoprotein, krv
